Advertisement

Topics

NEJM publishes second successful Epidiolex trial in LGS

07:34 EDT 17 May 2018 | PharmaTimes

The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.

Original Article: NEJM publishes second successful Epidiolex trial in LGS

NEXT ARTICLE

More From BioPortfolio on "NEJM publishes second successful Epidiolex trial in LGS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...